Thirty-year cardiovascular risk in patients with newly diagnosed bipolar disorder and their healthy first-degree relatives

2019 ◽  
Vol 29 ◽  
pp. S347-S348
Author(s):  
K. Coello ◽  
H. Kjærstad ◽  
S. Stanislaus ◽  
S. Melbye ◽  
M. Fauerholt-Jepsen ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Cardiovascular Risk ◽  
Newly Diagnosed ◽  
First Degree Relatives

Thirty-year cardiovascular risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives

2018 ◽  
Vol 53 (7) ◽  
pp. 651-662 ◽  
Author(s):  
Klara Coello ◽  
Hanne L Kjærstad ◽  
Sharleny Stanislaus ◽  
Sigurd Melbye ◽  
Maria Faurholt-Jepsen ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Bipolar Disorder ◽  
Cardiovascular Risk ◽  
Risk Score ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Newly Diagnosed ◽  
Healthy Individuals ◽  
First Degree Relatives ◽  
Age And Sex

Objectives: Bipolar disorder is associated with a decreased life expectancy of 8–12 years. Cardiovascular disease is the leading cause of excess mortality. For the first time, we investigated the Framingham 30-year risk score of cardiovascular disease in patients with newly diagnosed/first-episode bipolar disorder, their unaffected first-degree relatives and healthy individuals. Methods: In a cross-sectional study, we compared the Framingham 30-year risk score of cardiovascular disease in 221 patients with newly diagnosed/first-episode bipolar disorder, 50 of their unaffected first-degree relatives and 119 healthy age- and sex-matched individuals with no personal or first-degree family history of affective disorder. Among patients with bipolar disorder, we further investigated medication- and illness-related variables associated with cardiovascular risk. Results: The 30-year risk of cardiovascular disease was 98.5% higher in patients with bipolar disorder ( p = 0.017) and 85.4% higher in unaffected first-degree relatives ( p = 0.042) compared with healthy individuals in models adjusted for age and sex. When categorizing participants in low cardiovascular risk without considering age and sex distribution among participants, 81% of patients were at low risk, versus 92% of unaffected relatives and 89% of healthy individuals. Of the patients 209 (94.6%) were diagnosed within the preceding 2 years. Smoking was more prevalent among patients with bipolar disorder (45.2%) and their unaffected first-degree relatives (20.4%) compared with healthy individuals (12.8%). Similarly, dyslipidemia was more common among patients with bipolar disorder compared with healthy individuals. Treatment with psychotropic medication with metabolic adverse effects was associated with higher 30-year cardiovascular disease risk score, whereas we did not find illness-related variables associated with cardiovascular risk among patients with bipolar disorder. Conclusion: We found an enhanced cardiovascular disease risk score in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives, which points to a need for specific primary preventive interventions against smoking and dyslipidemia in these populations.

Hair cortisol in newly diagnosed bipolar disorder and unaffected first-degree relatives

2019 ◽  
Vol 99 ◽  
pp. 183-190 ◽  
Author(s):  
Klara Coello ◽  
Klaus Munkholm ◽  
Flemming Nielsen ◽  
Maj Vinberg ◽  
Lars Vedel Kessing
Keyword(s):  
Bipolar Disorder ◽  
Newly Diagnosed ◽  
Hair Cortisol ◽  
First Degree Relatives

scholarly journals Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls

BJPsych Open ◽  
2021 ◽  
Vol 7 (2) ◽  
Author(s):  
Nanna Aagaard Petersen ◽  
Marc Østergaard Nielsen ◽  
Klara Coello ◽  
Sharleny Stanislaus ◽  
Sigurd Melbye ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Newly Diagnosed ◽  
First Degree Relatives ◽  
Duration Of Illness ◽  
And Gender ◽  
Medication Status

Background Brain-derived neurotrophic factor (BDNF), which facilitates neuroplasticity and synaptogenesis, may be decreased in bipolar disorder, but has not been systematically investigated in people with newly diagnosed bipolar disorder and unaffected first-degree relatives. Aims To compare BDNF levels in patients with newly diagnosed bipolar disorder, their unaffected first-degree relatives and healthy controls. Method The study investigated plasma BDNF levels in patients (n = 371) with newly diagnosed bipolar disorder, their unaffected first-degree relatives (n = 98) and healthy controls (n = 200) using enzyme-linked immunosorbent assay. We further investigated associations between BDNF levels and illness-related variables and medication status. Results BDNF levels were found to be 22.0% (95% CI 1.107–1.343) higher in patients with bipolar disorder compared with healthy controls (P < 0.001) and 15.6% higher in unaffected first-degree relatives compared with healthy controls (95% CI 1.007–1.327, P = 0.04), when adjusting for age and gender. Further, BDNF levels were positively associated with duration of illness at a trend level (P = 0.05), age (P = 0.001) and use of anti-epileptic medication (P = 0.05). Conclusions These findings suggest that BDNF levels are not decreased in the early stages of bipolar disorder and in unaffected first-degree relatives contrasting with prior findings during later stages of the illness.

Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives

2019 ◽  
Vol 75 ◽  
pp. 112-118 ◽  
Author(s):  
Klara Coello ◽  
Tue Haldor Hansen ◽  
Nikolaj Sørensen ◽  
Klaus Munkholm ◽  
Lars Vedel Kessing ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Gut Microbiota ◽  
Microbiota Composition ◽  
Newly Diagnosed ◽  
First Degree Relatives ◽  
Gut Microbiota Composition

scholarly journals Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives

2019 ◽  
Vol 7 (1) ◽  
Author(s):  
Klara Coello ◽  
Maj Vinberg ◽  
Filip K. Knop ◽  
Bente K. Pedersen ◽  
Roger S. McIntyre ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Metabolic Profile ◽  
Newly Diagnosed ◽  
First Degree Relatives

scholarly journals High-sensitive C-reactive protein and homocysteine levels in patients with newly diagnosed bipolar disorder, their first-degree relatives, and healthy control persons—Results from a clinical study

2020 ◽  
Vol 63 (1) ◽  
Author(s):  
Marc Østergaard Nielsen ◽  
Nanna Aagaard Petersen ◽  
Klara Coello ◽  
Sharleny Stanislaus ◽  
Sigurd A. Melbye ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Activity Levels ◽  
Newly Diagnosed ◽  
C Reactive Protein ◽  
Metabolic Markers ◽  
Reactive Protein ◽  
First Degree Relatives ◽  
Affective Symptoms ◽  
Healthy Control ◽  
Hs Crp

Abstract Background Changes in inflammatory and metabolic markers are implicated in the pathogenesis in both the development and progression of bipolar disorder (BD). Notwithstanding, these markers have not been investigated in newly diagnosed BD. Methods We compared high-sensitive C-reactive protein (hs-CRP) and homocysteine (Hcy) levels in 372 patients with newly diagnosed BD, 106 unaffected first-degree relatives (URs), and 201 healthy control persons (HCs). Within the patient group, we also investigated possible associations between hs-CRP and Hcy, respectively, with illness-related characteristics and psychotropic medication. Results No statistically significant differences in Hcy and hs-CRP levels were found when comparing BD and URs with HCs. Similarly, there were no differences when comparing only patients in remission or patients with affective symptoms, respectively, with HCs. Hcy levels were found to be 11.9% (95% CI: 1.030–1.219) higher in patients with BD when compared with their URs (p = 0.008), when adjusting for folate and cobalamin status, age, sex, and self-reported activity levels. Hcy levels were significantly associated with folate, cobalamin, gender, and age in all models (p < 0.05). Conclusion Our results do not support hs-CRP or Hcy as markers in newly diagnosed BD.

Sign in / Sign up

Export Citation Format

Share Document